Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 9/20 | 0.49 |
| ▸ | PRKD2 | Q9BZL6 | 7/20 | 0.49 |
| ▸ | BRD4 | O60885 | 3/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ATAD2 | Q6PL18 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5386930 | 0.91 | BRD4 (0.48) | PRKCZPRKD2BRD4KCNH2ALDH1A1 | |
| SCHEMBL27583230 | 0.79 | PRKCZ (0.52) | PRKCZPRKD2BRD4CHEK1KCNH2 | |
| SCHEMBL12676577 | 0.75 | PRKCZ (0.49) | PRKCZPRKD2CHEK1FLT3 | |
| SCHEMBL19675966 | 0.75 | PRKCZ (0.52) | PRKCZPRKD2CHEK1KCNH2 | |
| SCHEMBL31357223 | 0.75 | PRKCZ (0.52) | PRKCZPRKD2CHEK1KCNH2 | |
| SCHEMBL5395259 | 0.74 | CHEK1 (0.41) | PRKCZPRKD2BRD4CHEK1MAPT | |
| SCHEMBL9310589 | 0.74 | PRKCZ (0.53) | PRKCZPRKD2BRD4ALDH1A1LMNA | |
| SCHEMBL5403382 | 0.73 | BRD4 (0.43) | PRKCZPRKD2BRD4KCNH2ATAD2 | |
| SCHEMBL10192579 | 0.73 | KAT2B (0.45) | ALDH1A1LMNAMAPTCRHBPCRHR2 | |
| SCHEMBL8236935 | 0.73 | KDM4E (0.65) | PRKCZPRKD2CHEK1KCNH2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | PRKCZ 157/4885PRKD2 368/4885BRD4 469/4885 |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | PRKCZ 733/4885PRKD2 220/4885BRD4 248/4885 |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | PAK2, PAK3, PAK4 | PRKCZ 207/4885PRKD2 309/4885BRD4 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.